



Chronic Malignancies Working Party

CML & MDS & PH-neg MPN

Chair: Donal McLornan


Secretaries: Joanna Drozd-Sokolowska & Kavita Raj

Data management: Linda Koster, Laurien Baaij, Joe Tuffnell

Statisticians: Dirk-Jan Eikema, Luuk Gras, Simona Iacobelli

Subcommittee Chronic Myeloid Leukemia (CML)

Chair: Yves Chalandon, Vice-chair: Guillermo Orti, Vice-chair: Hugues de Lavallade



Studies starting soon

Impact of TKI discontinuation in CML patients who have previously restarted TKI following allogeneic HSCT - *Hugues de Lavallade*

Prognostic value of additional cytogenetic abnormalities at transplantation in CML patients - *Jo Caers & Gaëlle Vertenoël*

Retrospective study on 2GTKi and 3GTKi after alloHSCT for CML in CP - *Yves Chalandon*

Upcoming manuscripts

Graft-versus-Host Disease Prophylaxis with Post Transplant Cyclophosphamide in Chronic Myeloid Leukemia patients undergoing Allogeneic Hematopoietic Cell Transplant from either an Unrelated or Mismatched Related Donor: a comparative study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT) – *Guillermo Orti*

Haplo-identical Donor Allogeneic transplantation compared to other donor types for Ph+ Chronic Myeloid Leukemia: a Retrospective Analysis from the Chronic Malignancies Working Party (CMWP) of the EBMT – *Francesco Onida*

Recent publication


Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party of the EBMT – *Y. Chalandon et al. American Journal of Hematology. 2023 Jan;98(1):112-121. doi:10.1002/ajh.26764*

Data Quality Initiative (DQI)

Fifty-four centers, comprising 702 patients, have participated in the CML Data Quality Initiative. The data will be utilized for various studies in the future.

Subcommittee Myelodysplastic Syndromes (MDS)

Chair: Marie Robin, Vice-chair: Christof Scheid, Vice-chair: Carmelo Gurnari, CMML: Francesco Onida



Oral Session 17: MDS and MPNs – Wednesday April 26th, 2023, 12:30 – 13:45

Location: Room 153

12:57 – 13:06 OS17-04 Outcomes of CMML patients undergoing Allogeneic HCT in comparison with MDS patients - A Retrospective Analysis on behalf of the CMWP of the EBMT - *Alicia Rovó*

Oral Session 5: GvHD (Clinical) – Wednesday April 26th, 2023, 10:30 -11:45

Location: Amphitheatre Bleu

11:15 – 11:24 OS05-06 GvHD Prophylaxis incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the CMWP of the EBMT - *Thomas Luft*

Posters


P007 – Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm following treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT - *Mitja Nabergoj*

P046 – Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms following treatment for Myeloma - *Sarah Lawless*

P303 Efficacy Of PTCY-Based GVHD-Prophylaxis In Adults Older Than 55 With Myeloid Malignancies Undergoing Allo-HCT According To Donor Type - *Queralto Salas*

Subcommittee PH1-neg Myeloproliferative Neoplasms (MPN)

Chair: Juan Carlos Hernández-Boluda, Vice-chair: Tomasz Czerw, Vice-chair: Nicola Polverelli



Ongoing studies

Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic stem cell transplantation in Myelofibrosis: an International analysis on behalf of the Chronic Malignancies Working Party of EBMT - *Nicola Polverelli*

A retrospective analysis of transplantation outcome for individuals with Advanced Systemic Mastocytosis (Adv-SM): Aggressive Systemic Mastocytosis (ASM), Systemic Mastocytosis with Associated Hematologic Disease (SM-AHD), Mast-Cell Leukemia (MCL) and Mast Cell Sarcoma (MCS) – *Ghandi Damaj*

Treosulfan in conditioning regimen before allogeneic HSCT in myelofibrosis patients – *Marie Robin*

Impact of CD34+ cell grafts content on clinical outcomes after family mismatched allo-HCT for myelofibrosis - *Tomasz Czerw*

Oral Session 17: MDS and MPNs – Wednesday April 26th, 2023, 12:30 – 13:45

Location: Room 153

16:15 – 16:24 OS17-01 Impact of Comorbidities and BMI on the outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: An International Analysis on behalf of the CMWP of EBMT - *Nicola Polverelli*

Chronic Malignancies Working Party Session - EBMT 2023 Challenges and Controversies in Allo-HCT for Myelofibrosis

Monday April 24th, 2023, 11:00 – 12:15

Location: Amphitheatre Bleu (On-site & Live stream)

Chairs: Donal McLornan & Kavita Raj

11:00 – 11:15 Utilising molecular data to guide the transplant decision in Myelofibrosis - *Katja Sockel*

11:15 – 11:30 Optimal management of splenomegaly pre-transplant - *Nicola Polverelli*

11:30 – 11:45 Selecting the best donor and stem cell source in allo-HCT for Myelofibrosis - *Tomasz Czerw*

11:45 – 12:00 Selecting the best conditioning regimen (+/-GVHD prophylaxis) in allo-HCT for Myelofibrosis - *Juan Carlos Hernández Boluda*

12:00 – 12:15 Panel Discussion and Questions

Chronic Malignancies Working Party Business Meeting EBMT 2023

Monday April 24th, 2023, 7:00 – 08:45

Location: Room 241